COVID-19 trials registries data warehouse

 Return to trial list

Trial - NCT04565379


Column Value
Trial registration number NCT04565379
Full text link
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

First author
Last imported at : Jan. 29, 2022, 11:30 a.m.
Source : ClinicalTrials.gov

Seung-Yong Seong, Dr.

Contact
Last imported at : Jan. 29, 2022, 11:30 a.m.
Source : ClinicalTrials.gov

David Song, shsong@shaperon.com (PI email not reported)

Registration date
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

2020-09-25

Recruitment status
Last imported at : Jan. 29, 2022, 11:30 a.m.
Source : ClinicalTrials.gov

Completed

Study design
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

RCT

Allocation
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Randomized

Design
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Parallel

Masking
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Blind label

Center
Last imported at : March 15, 2023, 4 a.m.
Source : ClinicalTrials.gov

multi-center

Study aim
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Treatment

Inclusion criteria
Last imported at : Nov. 16, 2021, 6:30 p.m.
Source : ClinicalTrials.gov

inclusion criteria male or female subjects aged between 18≤ and <80 years old laboratory-confirmed sars-cov-2 infection by pcr test for the first time within 144 hours prior to randomization diagnosis of pneumonia based on: radiographic infiltrates by imaging (chest x-ray, ct scan) and 3 of the following clinical symptoms: new onset cough, fever, fatigue, sputum (all day), tachypnea, dyspnea, pleuritic chest pain and crp value > 10 mg/l patients with blood leukocyte count > 4.0 x 109 /l and lymphocyte count > 0.7 x 109 l patients with spo2 ≤ 94% on room air or pa02/fi02 ratio < 300mghg at screening patients capable to give consent and who have signed the informed consent form before any trial related assessment. medically accepted effective contraception for women of childbearing potential (wocbp) which should be continued until at least 90 days after the last dose of trial treatment. patients with news2 score > 7 exclusion criteria alanine transaminase (alt) or aspartate transaminase (ast) > 5 times the upper limit of normal. reduced renal function with estimated glomerular filtration rate (egfr) < 30 ml/min or hemodialysis or hemofiltration. pregnancy or breast feeding. evidence of multiorgan failure steroid treatment by any reason within 72 hours prior to enrolment participation in any other clinical trial of an experimental agent treatment for covid-19 physician makes a decision that trial involvement is not in patients' best interest, or any condition that does not allow the protocol to be followed safely.

Exclusion criteria
Last imported at : March 19, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

None

Number of arms
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

3

Funding
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Shaperon

Inclusion age min
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

18

Inclusion age max
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

79

Countries
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Romania

Type of patients
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Severe/critical disease at enrollment

Severity scale
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

7: Severe/critical disease at enrollment

Total sample size
Last imported at : Jan. 29, 2022, 11:30 a.m.
Source : ClinicalTrials.gov

64

primary outcome
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Difference in Time to Clinical Improvement (TTCI) between the 2 treatments and the placebo group (in days)

Notes
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

None

Phase
Last imported at : Feb. 25, 2021, 7:58 p.m.
Source : ClinicalTrials.gov

Phase 2

Arms
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

[{"arm_notes": "", "treatment_id": 914, "treatment_name": "Nusepin", "treatment_type": "Others pharmacological treatment", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 914, "treatment_name": "Nusepin", "treatment_type": "Others pharmacological treatment", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]